Written by Keen Meds  ·  Reviewed by Licensed Clinical Providers  ·  March 1, 2026

Key Insight: Target range for monitored TRT: 400-700 ng/dL total testosterone. Hematocrit threshold for action: 54%. Both markers measured at the 3-month panel.

> Target range for monitored TRT: 400-700 ng/dL total testosterone. Hematocrit threshold for action: 54%. Both markers measured at the 3-month panel.

Medically reviewed by licensed clinical providers · March 2026

Starting testosterone replacement therapy is the beginning, not the end, of a clinical process. The 3-month blood panel is the first major checkpoint -- the moment where laboratory data replaces initial assumptions and the prescribing clinician can confirm whether levels are therapeutic, whether dose adjustment is needed, and whether any safety markers are trending outside acceptable range. Understanding what this panel includes, what each marker means, and what happens based on the results helps men engage with their TRT program as active participants rather than passive recipients.

Why 3 Months Is the Standard Interval

Three months is not an arbitrary calendar point. It reflects several clinical realities that converge at that interval:

First, steady-state testosterone levels are well established by 3 months for all common delivery methods. For transdermal spray, steady state is reached within days. For longer-acting injectables, it may take several weeks. By 3 months, any delivery method has had time to stabilize.

Second, 3 months is long enough to observe early clinical effects -- libido, energy, mood -- and correlate them with measured levels. A man who reports no improvement at 3 months can be evaluated in context of his actual testosterone concentration, not just his prescribed dose.

Third, 3 months is short enough to catch emerging safety signals before they become significant. Polycythemia (elevated red blood cell mass, reflected in hematocrit) develops gradually. Catching a rising hematocrit at 3 months allows for management -- dose adjustment, increased hydration, phlebotomy if needed -- before the threshold requiring urgent action is reached.

What the 3-Month Panel Includes

Total Testosterone

The primary marker. Reported in nanograms per deciliter (ng/dL). The target therapeutic range for monitored TRT is 400 to 700 ng/dL. This is the mid-physiological range -- high enough to produce clinical benefit, low enough to minimize risks associated with supraphysiological exposure.

Many labs report "normal range" as something like 264 to 916 ng/dL. That range is a population reference, not a treatment target. A man on TRT who tests at 310 ng/dL is technically in the lab's normal range but likely underdosed. A man at 850 ng/dL is in the lab's normal range but above the clinical target for managed therapy.

Free Testosterone

Total testosterone includes both protein-bound and unbound (free) testosterone. Only free testosterone is biologically active at the tissue level. Free T is particularly relevant for men with elevated SHBG (sex hormone-binding globulin), which binds testosterone and reduces bioavailability. Two men can have identical total T values but meaningfully different free T levels if their SHBG differs. The 3-month panel typically includes free T to provide a complete picture.

Hematocrit (Complete Blood Count)

Hematocrit is the percentage of blood volume composed of red blood cells. It is the most important safety marker monitored during TRT. Testosterone stimulates erythropoiesis (red blood cell production) -- a mechanism that can cause polycythemia (excess red blood cells) in some men. Polycythemia increases blood viscosity and is associated with elevated thrombotic risk.

Polycythemia occurs in approximately 2 to 5% of men on TRT. The clinical action threshold is hematocrit above 54%. Management options at that threshold include:

  • Dose reduction (the most common first step)
  • Increased hydration and avoidance of dehydration
  • Therapeutic phlebotomy (blood donation, which also lowers RBC volume)
  • Temporary hold of therapy pending normalization

Men with baseline hematocrit in the upper-normal range (50 to 52%) before starting TRT warrant closer monitoring at the 3-month interval, as they have less margin before reaching the threshold.

PSA (Prostate-Specific Antigen)

PSA is measured at baseline and again at 3 months. The clinical concern is not the absolute PSA value but the rate of change. A rapid rise of more than 1.4 ng/mL above baseline within the first 12 months is generally considered a signal warranting urological referral. The TRAVERSE prostate sub-study found no significant increase in prostate cancer incidence with testosterone therapy, but individual PSA monitoring remains standard of care for men over 40 on TRT.

LH and FSH (Optional, Based on Clinical Context)

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are pituitary hormones that regulate endogenous testosterone production. Exogenous testosterone suppresses the HPG axis, reducing LH and FSH -- and consequently reducing testicular testosterone production and sperm generation. These markers are not always included in routine 3-month panels, but they are relevant for men who have fertility concerns or who want to monitor HPG axis suppression.

Metabolic Panel

A basic or comprehensive metabolic panel is typically included to assess liver function, kidney function, glucose, and electrolytes. Testosterone has metabolic effects including improved insulin sensitivity, and tracking these markers over time helps characterize the full impact of therapy.

What Dose Adjustment Looks Like in Practice

Dose adjustment at the 3-month mark is common and does not indicate a failed start. It indicates that the prescribing clinician now has real data and is titrating to the appropriate target range.

Below 400 ng/dL at 3 months: The clinical team will typically increase the dose or review application consistency for transdermal delivery. Under-absorption is a common issue with transdermal products -- application to clean, dry, non-occluded skin matters, and consistent daily use is required for stable levels.

400 to 700 ng/dL at 3 months with improving symptoms: No change indicated. Continue current dose and retest at 6 months.

Above 700 ng/dL at 3 months: Dose reduction. Levels above 700 ng/dL do not add clinical benefit for most men and increase polycythemia risk. The goal is the mid-physiological range, not the upper limit.

Hematocrit above 54% at 3 months: Dose reduction as first step; additional management based on the degree of elevation.

The 6 to 12 Month Cadence

After the 3-month panel, stable patients typically move to a 6-month monitoring interval. At 12 months, the panel is often expanded -- particularly for PSA trends, bone density (in older men), and metabolic markers. The frequency of testing may increase again if dose adjustments are made or new symptoms emerge. Ongoing monitoring is not optional in responsible TRT management; it is the mechanism that keeps the therapy both effective and safe.

Frequently Asked Questions

Do I need to fast before a testosterone blood test during TRT monitoring?
For the initial diagnostic test, morning fasting is important because SHBG levels (which affect free testosterone) fluctuate with food intake, and testosterone peaks in the early morning hours. For subsequent monitoring panels during therapy, some providers still prefer morning draws for consistency, though the timing requirement is somewhat less strict for monitoring than for diagnosis. Follow your clinical team's instructions on timing and fasting for your specific panel.

What happens if my hematocrit hits 54% at the 3-month test?
A hematocrit of 54% is the action threshold, not an emergency cutoff. Your clinical team will most likely recommend a dose reduction and a recheck in 4 to 6 weeks. In some cases, therapeutic phlebotomy (blood donation) is recommended to reduce red blood cell volume more quickly. The goal is to bring hematocrit back below 52%, which is generally considered safe for continued therapy. Therapy is rarely discontinued permanently for isolated hematocrit elevation.

Is a PSA rise on TRT dangerous?
A PSA rise while on TRT warrants evaluation rather than alarm. A modest PSA increase is not uncommon early in therapy, particularly in men who were borderline hypogonadal and had been running low androgens. The clinical signal of concern is a rapid rise -- more than 1.4 ng/mL above baseline in the first 12 months -- which prompts urological referral. TRT does not cause prostate cancer, but it may accelerate the growth of pre-existing cancer. This is why baseline PSA and monitoring are required.

Know Your Numbers. Manage Your Therapy.

The 3-month blood panel is not a formality -- it is the clinical foundation of responsible TRT. Understanding your total T, free T, hematocrit, and PSA trends puts you in an informed position to work with your provider and get the most out of treatment.

Keen Meds connects you with a licensed clinical team for a telehealth consultation and lab review. If your testosterone is clinically low, you receive a prescription for Testosterone Spray Rx -- delivered via Hypospray®, Keen's needle-free transdermal spray platform.

Start your Keen Testosterone Spray Program →

Medically reviewed by Licensed Clinical Providers · March 2026

Related reading: